STEMCELL-TECHNOLOGIES
STEMCELL Technologies and Hubrecht Organoid Technology (HUB) have announced that they have signed an agreement for the use of tissue-derived organoids—including lung, intestinal, and liver organoids—for use in preclinical toxicology screening and non-cancer drug development services to be offered by the Contract Assay Services division of STEMCELL. These services will help researchers and organizations working on drug development incorporate organoids into their preclinical testing programs and bring new therapeutics to market faster and more cost-effectively.
HUB Organoids™ are experimental models derived from the adult stem cells present in epithelial tissues. Expansion and differentiation of these stem cells gives rise to functional “mini-organs in a dish”. HUB Organoids™ represent a patient-specific way of assessing the efficacy and toxicity of drugs during preclinical screening. By closely mimicking human biology, HUB Organoids™ can be used to more accurately predict patient response to treatment than traditionally used systems. As such, they have the potential to drastically lower the costs and failure rates currently associated with bringing new treatments to market. Under the existing agreement, STEMCELL develops and supplies a wide range of cell culture kits that efficiently expand and maintain the different stem cell-derived organoids that will be used for many of these screening programs.
This new agreement complements HUB and STEMCELL’s existing partnership, where STEMCELL is the exclusive provider of cell culture media for all HUB Organoids™, by allowing STEMCELL to perform preclinical toxicology screening as well as non-cancer drug testing and validation services. "We are extremely pleased to be able to expand our partnership with HUB to include these new services," remarked Dr. Allen Eaves, STEMCELL’s Founder, President, and CEO. "As Scientists Helping Scientists, our goal is to make these incredible technologies more accessible to researchers, whether they are growing organoids in their own labs or partnering with service providers to advance their science."
“At HUB we are on a mission to bridge the gap between the lab and the clinic and bring patients-specific models into the lab,” said Dr. Robert Vries, HUB CEO. “Carefully selecting our strategic partners is key to expanding global access to HUB Organoid Technology and, ultimately, to improving patient care. STEMCELL has already demonstrated thought leadership in the Organoid Technology field; therefore, we believe that expanding the scope of our partnership to include services will benefit the research and drug development community worldwide.”
About STEMCELL Technologies
As Scientists Helping Scientists, STEMCELL Technologies is committed to providing high-quality cell culture media, cell isolation products, accessory reagents and services for life science research. Driven by science and a passion for quality, STEMCELL Technologies offers over 2500 products designed to support the basic to translational research continuum. Visit www.stemcell.com to learn more.
About HUB
Hubrecht Organoid Technology (HUB) was founded by the Hubrecht Institute, the University Medical Center Utrecht, and the Royal Netherlands Academy of Arts and Sciences (KNAW) to refine organoid development and foster organoid adoption globally. HUB Organoid Technology represents a paradigm-shift that bridges the gap between the lab and the clinic and effectively brings “patients in the lab” for drug discovery and development, preclinical patient stratification, predictive biomarker discovery, personalized medicine, clinical trials, regenerative medicine, and companion diagnostics applications. Learn more by visiting www.huborganoids.nl
View source version on businesswire.com: https://www.businesswire.com/news/home/20210818005144/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kaneka Expands Global Reach with i-ED COIL™ Launch in Europe10.11.2025 03:51:00 CET | Press release
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii) (TOKYO:4118) has begun sales of its i-ED COIL™, a brain aneurysm embolization coil (*1), in Europe as of October. The product obtained EC certification (*2) under an EU Medical Device Regulation (*3) in July and will be distributed primarily in Europe through Kaneka Medical Europe N.V. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251109744229/en/ i-ED Coil The i-ED COIL™ provides world-class flexibility, enabled by its specialized wire thickness and structural features. This flexibility enables coils to be packed more densely within aneurysms than conventional products and allows treatment of aneurysms with irregular shapes. Its role in reducing the risk of aneurysm rupture is highly regarded by physicians, and since its launch in the Japanese market in 2019, sales have continued to grow steadily. Kaneka is expanding its business in a wide range
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week8.11.2025 23:15:00 CET | Press release
- 48-week data show a 64% decrease from baseline in proteinuria in IgA nephropathy, 82% decrease from baseline in proteinuria in primary membranous nephropathy, and stabilization of estimated glomerular filtration rate across both diseases - - Vertex on track to initiate rolling submission of Biologics License Application for potential accelerated approval to the U.S. Food and Drug Administration this year; full enrollment completed for Phase 3 RAINIER trial in IgA nephropathy - - Povetacicept in primary membranous nephropathy granted Fast Track Designation by the U.S. Food and Drug Administration and Phase 2/3 pivotal trial initiated - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas. Pove is an investigational recombinant fusion protein therapeutic and dual
Westinghouse and Hungary Establish Landmark Nuclear Fuel Partnership8.11.2025 15:00:00 CET | Press release
First Contract Signed with MVM Group to Deliver VVER-440 Fuel to Paks Nuclear Power Plant Westinghouse Electric Company and MVM Group signed a contract to ensure diversification of fuel supply in Hungary. This partnership brings to Paks Nuclear Power Plant (NPP) reliable supply with Westinghouse VVER fuel, manufactured in Europe. The Westinghouse VVER-440 fuel reload deliveries will start in 2028, subject to licensing activities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107682814/en/ Westinghouse Nuclear Fuel Senior Vice President Aziz Dag, left, and Károly Mátrai, CEO of the MVM Group, signed the Paks VVER-440 contract, Nov. 7, 2025. “Our agreement with Westinghouse is a clear response to today's energy challenges and further strengthens the role of Hungary's leading base power plant in the domestic energy supply. This strategically important step will make the operation of Paks Nuclear Power Plant safer and more f
OMRON Releases the “Medium-Term Roadmap SF 2nd Stage”8.11.2025 07:00:00 CET | Press release
OMRON (TOKYO: 6645) has announced its “Medium-Term Roadmap Shaping the Future 2nd Stage (“SF 2nd Stage”),” covering from FY2026 to FY2030, on November 7, 2025 (JST). This Roadmap presents the Group’s vision and growth strategies through 2030, which are disclosed on our corporate website. Overview of the “Medium-Term Roadmap SF 2nd Stage” Since April 2024, OMRON has been implementing a Structural Reform Program “NEXT 2025” aimed at rebuilding our foundation for profitability and growth. With the completion of this Program in September 2025, we have shifted into a growth phase and formulated a new Roadmap looking ahead to 2030. This Roadmap identifies Business Portfolio Restructuring as a core strategy. We have defined Thirteen Focus Businesses to drive the Group’s future growth. By accelerating our selection and concentration efforts, we aim to build a “distinctive” business portfolio that maximizes overall Group growth. Furthermore, to maximize the growth potential of our Focus Busines
26th UN Tourism General Assembly kicks off in Riyadh7.11.2025 22:13:00 CET | Press release
UN Tourism marks 50 years of global cooperation as leaders from across the industry gather to shape the future of tourism. His Excellency Ahmed Al Khateeb, Minister of Tourism – “The Kingdom will play an integral part in ensuring one of the world’s most powerful generators of jobs and GDP grows in harmony with the Sustainable Development Goals.” UN Tourism Secretary-General ZurabPololikashvili – “The UN Tourism General Assembly brings together tourism leaders from across the world to set the agenda and build a more innovative and inclusive sector. From Riyadh, we will set the agenda for tourism for the years ahead.” The 26th session of the UN Tourism General Assembly opened today in Riyadh, marking a historic first for the Gulf Cooperation Council (GCC) region and the largest Assembly since UN Tourism was founded 50 years ago. Around 160 delegations from member states including ministers, senior officials, and leaders from across industry and civil society are coming together to celebr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom